A股異動 | 景峯醫藥漲停 子公司獲得口罩生產許可
格隆匯4月7日丨景峯醫藥(000908.SZ)漲停,現報4.35元,暫成交1.42億元,最新總市值38億元。景峯醫藥昨日盤後公佈,近日,公司之子公司貴州景峯收到貴州省藥品監督管理局下發的《貴州省醫療器械疫情應急註冊證》及貴陽市市場監督管理局下發的《關於同意貴州景峯注射劑有限公司臨時生產一次性使用非無菌口罩的函》。貴州景峯此次口罩相關資質的取得,將進一步豐富產品種類,對公司具有積極意義。公告還稱,口罩產品預計產生的收入佔公司全年營業收入的比重很小,對公司經營業績不會產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.